Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Research in two fronts has enabled the development of therapies that provide significant
benefit to cancer patients. One area stems from a detailed knowledge of mutations that …

Immune check point inhibitors (ICIs) have marked their existence in the field of cancer
immunotherapy. Their existence dates to 2011 when the first anti-cytotoxic T lymphocyte …

Immune checkpoint inhibitors (ICI) have emerged as a remarkable treatment option for
diverse cancer types. Currently, ICIs are approved for an expanding array of cancer …

Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely
associated with ICI therapies, which not only will rejuvenate our assessment of ICI …

Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade
therapies unleash breaks in the immune system and induce long-lasting responses …

Even though the immuno-oncology (IO) era has achieved many successes, some signs of
research development deceleration are arising. Recently, the number of FDA …

Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-
tolerance and assist with immune response. In cancer, immune checkpoint pathways are …